Zhaoke Ophthalmology partners with PT Ferron for presbyopia drug in Indonesia

Zhaoke Ophthalmology Limited (Zhaoke) has finalized a distribution and supply agreement with PT Ferron Par Pharmaceuticals (PT Ferron), a leading Indonesian pharmaceutical company, for the commercialization of BRIMOCHOL™ PF in Indonesia. BRIMOCHOL™ PF, an innovative drug for presbyopia treatment, is licensed from Tenpoint Therapeutics, Ltd. Under the agreement, Zhaoke grants PT Ferron exclusive rights to import, promote, distribute, market, and sell the product within Indonesia. Zhaoke will receive an upfront payment and is eligible for additional milestone payments based on specific achievements.

BRIMOCHOL™ PF is an investigational, preservative-free, once-daily eyedrop designed to correct near vision loss associated with aging. Tenpoint Therapeutics announced in June 2025 that the U.S. FDA accepted the New Drug Application (NDA) for BRIMOCHOL™ PF, setting a Prescription Drug User Fee Act (PDUFA) date of January 28, 2026. The drug has completed two large Phase 3 pivotal trials, BRIO-I and BRIO-II.

Presbyopia, the gradual loss of near vision, affects billions globally, with approximately 600m adults impacted in China, South Korea, and Southeast Asia. Currently, there are no approved presbyopia-correcting therapeutics in many Asia-Pacific countries. This partnership aims to address this unmet medical need in Indonesia.